Editas Medicine (EDIT)
(Delayed Data from NSDQ)
$5.37 USD
+0.05 (0.94%)
Updated Apr 29, 2024 03:59 PM ET
After-Market: $5.36 -0.01 (-0.19%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth B Momentum D VGM
Editas Medicine (EDIT) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$15.23 | $27.00 | $7.00 | 186.28% |
Price Target
Based on short-term price targets offered by 13 analysts, the average price target for Editas Medicine comes to $15.23. The forecasts range from a low of $7.00 to a high of $27.00. The average price target represents an increase of 186.28% from the last closing price of $5.32.
Analyst Price Targets (13)
Broker Rating
Editas Medicine currently has an average brokerage recommendation (ABR) of 2.11 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 16 brokerage firms. The current ABR compares to an ABR of 2.11 a month ago based on 16 recommendations.
Of the 16 recommendations deriving the current ABR, seven are Strong Buy and one is Buy. Strong Buy and Buy respectively account for 43.75% and 6.25% of all recommendations. A month ago, Strong Buy made up 43.75%, while Buy represented 6.25%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 7 | 7 | 7 | 7 | 7 |
Buy | 1 | 1 | 1 | 1 | 1 |
Hold | 7 | 7 | 7 | 7 | 7 |
Sell | 1 | 1 | 1 | 1 | 1 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 2.11 | 2.11 | 2.11 | 2.11 | 2.11 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
4/1/2024 | Chardan Capital Markets | Yevgeniya Livshits | Strong Buy | Strong Buy |
12/12/2023 | Truist Securities | Joon Lee | Strong Buy | Strong Buy |
11/3/2023 | Robert W. Baird & Co. | Jack K Allen | Not Available | Strong Buy |
11/3/2023 | SVB Securities | Mani Foroohar | Hold | Hold |
11/3/2023 | Raymond James | Steven Seedhouse | Moderate Buy | Moderate Buy |
10/18/2023 | Cantor Fitzgerald & Co | Eric Schmidt | Hold | Hold |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 2.11 |
ABR (Last week) | 2.11 |
# of Recs in ABR | 16 |
Average Target Price | $15.23 |
LT Growth Rate | NA |
Industry | Medical - Biomedical and Genetics |
Industry Rank by ABR | 76 of 252 |
Current Quarter EPS Est: | -0.65 |